New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.

Abo-ouf H, Hooper AWM, White EJ et al (2013) Deletion of tumor necrosis factor-α ameliorates neurodegeneration in sandhoff disease mice. Hum Mol Genet 22:3960–3975. https://doi.org/10.1093/hmg/ddt250

doi: 10.1093/hmg/ddt250 pubmed: 23727835

Accogli T, Hibos C, Vegran F (2023) Canonical and non-canonical functions of NLRP3. J Adv Res 53:137–151. https://doi.org/10.1016/j.jare.2023.01.001

doi: 10.1016/j.jare.2023.01.001 pubmed: 36610670 pmcid: 10658328

Aganna E, Martinon F, Hawkins PN et al (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46:2445–2452. https://doi.org/10.1002/art.10509

doi: 10.1002/art.10509 pubmed: 12355493

Akhtar MW, Raingo J, Nelson ED et al (2009) Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J Neurosci 29:8288–8297. https://doi.org/10.1523/JNEUROSCI.0097-09.2009

doi: 10.1523/JNEUROSCI.0097-09.2009 pubmed: 19553468 pmcid: 2895817

Albornoz EA, Woodruff TM, Gordon R (2018) Inflammasomes in CNS Diseases. Exp Suppl 108:41–60. https://doi.org/10.1007/978-3-319-89390-7_3

doi: 10.1007/978-3-319-89390-7_3 pubmed: 30536167

Alcocer-Gómez E, de Miguel M, Casas-Barquero N et al (2014) NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun 36:111–117. https://doi.org/10.1016/j.bbi.2013.10.017

doi: 10.1016/j.bbi.2013.10.017 pubmed: 24513871

Aliaga J, Bonaventura A, Mezzaroma E, Dhakal Y, Mauro AG, Abbate A, Toldo S (2021) Preservation of contractile reserve and diastolic function by inhibiting the NLRP3 inflammasome with OLT1177® (dapansutrile) in a mouse model of severe ischemic cardiomyopathy due to non-reperfused anterior wall myocardial infarction. Molecules 26(12):3534. https://doi.org/10.3390/molecules26123534

doi: 10.3390/molecules26123534 pubmed: 34207886 pmcid: 8227554

Alishahi M, Farzaneh M, Ghaedrahmati F et al (2019) NLRP3 inflammasome in ischemic stroke: As possible therapeutic target. Int J Stroke 14:574–591. https://doi.org/10.1177/1747493019841242

doi: 10.1177/1747493019841242 pubmed: 30940045

Amo-Aparicio J, Garcia-Garcia J, Puigdomenech M et al (2022) Inhibition of the NLRP3 inflammasome by OLT1177 induces functional protection and myelin preservation after spinal cord injury. Exp Neurol 347:113889. https://doi.org/10.1016/j.expneurol.2021.113889

doi: 10.1016/j.expneurol.2021.113889 pubmed: 34624330

Arita Y, Yoshinaga Y, Kaneko T et al (2020) Glyburide inhibits the bone resorption induced by traumatic occlusion in rats. J Periodontal Res 55:464–471. https://doi.org/10.1111/jre.12731

doi: 10.1111/jre.12731 pubmed: 32153049

Arriola Benitez PC, Pesce Viglietti AI, Gomes MTR et al (2020) Brucella abortus infection elicited hepatic stellate cell-mediated fibrosis through inflammasome-dependent IL-1β production. Front Immunol 10:3036. https://doi.org/10.3389/fimmu.2019.03036

doi: 10.3389/fimmu.2019.03036 pubmed: 32038610 pmcid: 6985094

Atianand MK, Harton JA (2011) Uncoupling of pyrin-only protein 2 (POP2)-mediated dual regulation of NF-κB and the inflammasome. J Biol Chem 286:40536–40547. https://doi.org/10.1074/jbc.M111.274290

doi: 10.1074/jbc.M111.274290 pubmed: 21976665 pmcid: 3220484

Banjara M, Ghosh C (2017) Sterile neuroinflammation and strategies for therapeutic intervention. Int J Inflam 2017:8385961. https://doi.org/10.1155/2017/8385961

doi: 10.1155/2017/8385961 pubmed: 28127491 pmcid: 5239986

Banoth B, Cassel SL (2017) Bruton tyrosine kinase inhibition: Clinical relevance beyond B cells. J Allergy Clin Immunol 140:985–987. https://doi.org/10.1016/j.jaci.2017.03.041

doi: 10.1016/j.jaci.2017.03.041 pubmed: 28456622

Batista PJ, Chang HY (2013) Long noncoding RNAs: Cellular address codes in development and disease. Cell 152:1298–1307. https://doi.org/10.1016/j.cell.2013.02.012

doi: 10.1016/j.cell.2013.02.012 pubmed: 23498938 pmcid: 3651923

Bayarsaihan D (2011) Epigenetic mechanisms in inflammation. J Dent Res 90:9–17. https://doi.org/10.1177/0022034510378683

doi: 10.1177/0022034510378683 pubmed: 21178119 pmcid: 3144097

Bedoya F, Sandler LL, Harton JA (2007) Pyrin-Only Protein 2 Modulates NF-κB and Disrupts ASC:CLR Interactions. J Immunol 178:3837–3845. https://doi.org/10.4049/jimmunol.178.6.3837

doi: 10.4049/jimmunol.178.6.3837 pubmed: 17339483

Bellezza I, Grottelli S, Costanzi E et al (2018) Peroxynitrite Activates the NLRP3 Inflammasome Cascade in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol Neurobiol 55:2350–2361. https://doi.org/10.1007/s12035-017-0502-x

doi: 10.1007/s12035-017-0502-x pubmed: 28357805

Bhaumik SR, Smith E, Shilatifard A (2007) Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14:1008–1016. https://doi.org/10.1038/nsmb1337

doi: 10.1038/nsmb1337 pubmed: 17984963

Billingham LK, Stoolman JS, Vasan K et al (2022) Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. Nat Immunol 23:692–704. https://doi.org/10.1038/s41590-022-01185-3

doi: 10.1038/s41590-022-01185-3 pubmed: 35484407 pmcid: 9098388

Bishop E (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297. https://doi.org/10.1016/s0092-8674(04)00045-5

doi: 10.1016/s0092-8674(04)00045-5

Brocker CN, Kim D, Melia T et al (2020) Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting. Nat Commun 11(1):5847. https://doi.org/10.1038/s41467-020-19554-7

doi: 10.1038/s41467-020-19554-7 pubmed: 33203882 pmcid: 7673042

Brydges SD, Mueller JL, McGeough MD et al (2009) Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30:875–887. https://doi.org/10.1016/j.immuni.2009.05.005

doi: 10.1016/j.immuni.2009.05.005 pubmed: 19501000 pmcid: 2759865

Bulté D, Rigamonti C, Romano A, Mortellaro A (2023) Inflammasomes: mechanisms of action and involvement in human diseases. Cells 12(13):1766. https://doi.org/10.3390/cells12131766

doi: 10.3390/cells12131766 pubmed: 37443800 pmcid: 10340308

Cai LJ, Tu L, Huang XM et al (2020) LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease. Mol Brain 13:130. https://doi.org/10.1186/s13041-020-00656-8

doi: 10.1186/s13041-020-00656-8 pubmed: 32972446 pmcid: 7513532

Cao F, Deliz-Aguirre R, Gerpott FHU et al (2023) Myddosome clustering in IL-1 receptor signaling regulates the formation of an NF-kB activating signalosome. EMBO Rep 24(10):e57233. https://doi.org/10.15252/embr.202357233

doi: 10.15252/embr.202357233 pubmed: 37602973 pmcid: 10561168

Cao J, Peng Q (2022) NLRP3 Inhibitor tranilast attenuates gestational diabetes mellitus in a genetic mouse model. Drugs R D 22:105–112. https://doi.org/10.1007/s40268-022-00382-7

doi: 10.1007/s40268-022-00382-7 pubmed: 35124792 pmcid: 8885922

Carter C, Reid T, Fisher G et al (2015) Early results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer. Ann Oncol 26:ii3–ii5. https://doi.org/10.1093/annonc/mdv081.8

doi: 10.1093/annonc/mdv081.8

Carvalho AM, Novais FO, Paixão CS et al (2020) Glyburide, a NLRP3 inhibitor, decreases inflammatory response and is a candidate to reduce pathology in leishmania braziliensis infection. J Invest Dermatol 140:246-249.e2. https://doi.org/10.1016/j.jid.2019.05.025

doi: 10.1016/j.jid.2019.05.025 pubmed: 31252034

Chakrabarti M, Klionsky DJ, Ray SK (2016) miR-30e blocks autophagy and acts synergistically with proanthocyanidin for inhibition of AVEN and BIRC6 to increase apoptosis in glioblastoma stem cells and glioblastoma SNB19 cells. PLoS One 11(7):e0158537. https://doi.org/10.1371/journal.pone.0158537

doi: 10.1371/journal.pone.0158537 pubmed: 27388765 pmcid: 4936720

Chen CY, Peng WH, Tsai KD, Hsu SL (2007) Luteolin suppresses inflammation-associated gene expression by blocking NF-κB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci 81:1602–1614. https://doi.org/10.1016/j.lfs.2007.09.028

doi: 10.1016/j.lfs.2007.09.028 pubmed: 17977562 pmcid: 7094354

Chen H, Lu Q, Fei X et al (2016a) miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1. Tumor Biol 37:6761–6768. https://doi.org/10.1007/s13277-015-4575-8

doi: 10.1007/s13277-015-4575-8

Chen S, Liu J, Zhang H (2009) Efficacy of rabdosia rubescens in the treatment of gingivitis. J Huazhong Univ Sci Technol - Med Sci 29:659–663. https://doi.org/10.1007/s11596-009-0525-2

doi: 10.1007/s11596-009-0525-2

Chen WW, Zhang X, Huang WJ (2016b) Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 13:3391–3396. https://doi.org/10.3892/mmr.2016.4948

doi: 10.3892/mmr.2016.4948 pubmed: 26935478 pmcid: 4805095

Chen Y, He H, Lin B et al (2021) RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Cell Mol Immunol 18:1425–1436. https://doi.org/10.1038/s41423-021-00683-y

doi: 10.1038/s41423-021-00683-y pubmed: 33972740 pmcid: 8166941

Chen Y, Ye X, Escames G et al (2023) The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett 28(1):51. https://doi.org/10.1186/s11658-023-00462-9

doi: 10.1186/s11658-023-00462-9 pubmed: 37370025 pmcid: 10303833

Chen YL, Xu G, Liang X et al (2016c) Inhibition of hepatic cells pyroptosis attenuates CLP-induced acute liver injury. Am J Transl Res 8:5685–5695

pubmed: 28078039 pmcid: 5209519

Cheng J, Hao J, Jiang X et al (2021) Ameliorative effects of miR-423-5p against polarization of microglial cells of the M1 phenotype by targeting a NLRP3 inflammasome signaling pathway. Int Immunopharmacol 99:108006. https://doi.org/10.1016/j.intimp.2021.108006

doi: 10.1016/j.intimp.2021.108006 pubmed: 34339965

Chinta PK, Tambe S, Umrani D et al (2022) Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice. Can J Physiol Pharmacol 100:272–281. https://doi.org/10.1139/cjpp-2021-0116

doi: 10.1139/cjpp-2021-0116 pubmed: 35119950

Coll RC, Robertson AAB, Chae JJ et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248–257. https://doi.org/10.1038/nm.3806

doi: 10.1038/nm.3806 pubmed: 25686105 pmcid: 4392179

Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A (2011) The inflammasomes in health and disease: From genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol 8:135–145. https://doi.org/10.1038/cmi.2010.81

doi: 10.1038/cmi.2010.81 pubmed: 21258359 pmcid: 4003142

Cui ZY, Wang G, Zhang J et al (2021) Parthenolide, bioactive compound of Chrysanthemum parthenium L., ameliorates fibrogenesis and inflammation in hepatic fibrosis via regulating the crosstalk of TLR4 and STAT3 signaling pathway. Phyther Res 35:5680–5693. https://doi.org/10.1002/ptr.7214

doi: 10.1002/ptr.7214

Daniels MJD, Rivers-Auty J, Schilling T et al (2016) Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat Commun 7:1–10. https://doi.org/10.1038/ncomms12504

doi: 10.1038/ncomms12504

Darakhshan S, Pour AB (2015) Tranilast: A review of its therapeutic applications. Pharmacol Res 91:15–28. https://doi.org/10.1016/j.phrs.2014.10.009

doi: 10.1016/j.phrs.2014.10.009 pubmed: 25447595

de Almeida L, Khare S, Misharin AV et al (2015) The PYRIN Domain-only Protein POP1 Inhibits Inflammasome Assembly and Ameliorates Inflammatory Disease. Immunity 43:264–276. https://doi.org/10.1016/j.immuni.2015.07.018

doi: 10.1016/j.immuni.2015.07.018 pubmed: 26275995 pmcid: 4666005

Dempsey C, Rubio Araiz A, Bryson KJ et al (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun 61:306–316. https://doi.org/10.1016/j.bbi.2016.12.014

doi: 10.1016/j.bbi.2016.12.014 pubmed: 28003153

Deora V, Lee JD, Albornoz EA et al (2020) The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia 68:407–421. https://doi.org/10.1002/glia.23728

doi: 10.1002/glia.23728 pubmed: 31596526

Devi S, Stehlik C, Dorfleutner A (2020) An update on card only proteins (COPS) and pyd only proteins (POPS) as inflammasome regulators. Int J Mol Sci 21:1–18. https://doi.org/10.3390/ijms21186901

doi: 10.3390/ijms21186901

Ding J, Wang K, Liu W et al (2016a) Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535:111–116. https://doi.org/10.1038/nature18590

doi: 10.1038/nature18590 pubmed: 27281216

Ding Q, Shen L, Nie X et al (2018) MiR-223-3p overexpression inhibits cell proliferation and migration by regulating inflammation-associated cytokines in glioblastomas. Pathol Res Pract 214:1330–1339. https://doi.org/10.1016/j.prp.2018.05.012

doi: 10.1016/j.prp.2018.05.012 pubmed: 30033329

Ding W, Cai C, Zhu X et al (2022) Parthenolide ameliorates neurological deficits and neuroinflammation in mice with traumatic brain injury by suppressing STAT3/NF-κB and inflammasome activation. Int Immunopharmacol 108:108913. https://doi.org/10.1016/j.intimp.2022.108913

doi: 10.1016/j.intimp.2022.108913 pubmed: 35729839

Ding Y, Ding C, Ye N et al (2016b) Discovery and development of natural product oridonin-inspired anticancer agents. Eur J Med Chem 122:102–117. https://doi.org/10.1016/j.ejmech.2016.06.015

doi: 10.1016/j.ejmech.2016.06.015 pubmed: 27344488 pmcid: 5003635

Dong L, Qiao H, Zhang X et al (2013) Parthenolide is neuroprotective in rat experimental stroke model: downregulating NF- B, phospho-p38MAPK, and caspase-1 and ameliorating BBB permeability. Mediators Inflamm 2013:370804. https://doi.org/10.1155/2013/370804

doi: 10.1155/2013/370804 pubmed: 23935248 pmcid: 3725704

Dorfleutner A, Bryan NB, Talbott SJ et al (2007) Cellular pyrin domain-only protein 2 is a candidate regulator of inflammasome activation. Infect Immun 75:1484–1492. https://doi.org/10.1128/IAI.01315-06

doi: 10.1128/IAI.01315-06 pubmed: 17178784

Du H, Li CH, Gao RB et al (2024) Inhibition of the interaction between microglial adenosine 2A receptor and NLRP3 inflammasome attenuates neuroinflammation posttraumatic brain injury. CNS Neurosci Ther 30(1):e14408. https://doi.org/10.1111/cns.14408

doi: 10.1111/cns.14408 pubmed: 38334061 pmcid: 10853892

Duan R, Wang SY, Wei B et al (2021) Angiotensin-(1–7) Analogue AVE0991 Modulates Astrocyte-Mediated Neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 Pathway and Offers Neuroprotection in a Transgenic Mouse Model of Alzheimer’s Disease. J Inflamm Res 14:7007–7019. https://doi.org/10.2147/JIR.S343575

doi: 10.2147/JIR.S343575 pubmed: 34955647 pmcid: 8694579

Duan Y, Kelley N, He Y (2020) Role of the NLRP3 inflammasome in neurodegenerative diseases and therapeutic implications. Neural Regen Res 15:1249–1250. https://doi.org/10.4103/1673-5374.272576

doi: 10.4103/1673-5374.272576 pubmed: 31960806 pmcid: 7047811

Dubuisson N, Davis-López de Carrizosa MA, Versele R et al (2022) Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy. Front Immunol 13:1049076. https://doi.org/10.3389/fimmu.2022.1049076

doi: 10.3389/fimmu.2022.1049076 pubmed: 36569900 pmcid: 9770793

Duncan JA, Bergstralh DT, Wang Y et al (2007) Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci USA 104:8041–8046. https://doi.org/10.1073/pnas.0611496104

doi: 10.1073/pnas.0611496104 pubmed: 17483456 pmcid: 1876568

El-Khoury R, Dufour E, Rak M et al (2013) Alternative oxidase expression in the mouse enables bypassing cytochrome c oxidase blockade and limits mitochondrial ROS overproduction. PLoS Genet 9(1):e1003182. https://doi.org/10.1371/journal.pgen.1003182

doi: 10.1371/journal.pgen.1003182 pubmed: 23300486 pmcid: 3536694

Eren E, Özören N (2019) The NLRP3 inflammasome: A new player in neurological diseases. Turkish J Biol 43:349–359. https://doi.org/10.3906/biy-1909-31

doi: 10.3906/biy-1909-31

Fabbri M, Garzon R, Cimmino A et al (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104:15805–15810. https://doi.org/10.1073/pnas.0707628104

doi: 10.1073/pnas.0707628104 pubmed: 17890317 pmcid: 2000384

Fan K, Ma J, Xiao W et al (2017) Mangiferin attenuates blast-induced traumatic brain injury via inhibiting NLRP3 inflammasome. Chem Biol Interact 271:15–23. https://doi.org/10.1016/j.cbi.2017.04.021

doi: 10.1016/j.cbi.2017.04.021 pubmed: 28455230

Fan Y, Du L, Fu Q et al (2018) Inhibiting the NLRP3 inflammasome with MCC950 ameliorates isoflurane-induced pyroptosis and cognitive impairment in aged mice. Front Cell Neurosci 12:1–9. https://doi.org/10.3389/fncel.2018.00426

doi: 10.3389/fncel.2018.00426

Fan Z, Pan YT, Zhang ZY et al (2020) Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease. J Neuroinflammation 17(1):11. https://doi.org/10.1186/s12974-019-1670-6

doi: 10.1186/s12974-019-1670-6 pubmed: 31915018 pmcid: 6950934

Fang P, Chen C, Zheng F et al (2021) NLRP3 inflammasome inhibition by histone acetylation ameliorates sevoflurane-induced cognitive impairment in aged mice by activating the autophagy pathway. Brain Res Bull 172:79–88. https://doi.org/10.1016/j.brainresbull.2021.04.016

doi: 10.1016/j.brainresbull.2021.04.016 pubmed: 33895270

Fang Y, Hong X (2021) miR-124-3p inhibits microglial secondary inflammation after basal ganglia hemorrhage by targeting TRAF6 and repressing the activation of NLRP3 inflammasome. Front Neurol 12:653321. https://doi.org/10.3389/fneur.2021.653321

doi: 10.3389/fneur.2021.653321 pubmed: 34413820 pmcid: 8369369

Farrelly LA, Thompson RE, Zhao S et al (2019) Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature 567:535–539. https://doi.org/10.1038/s41586-019-1024-7

doi: 10.1038/s41586-019-1024-7 pubmed: 30867594 pmcid: 6557285

Feigin VL, Nichols E, Alam T et al (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459–480. https://doi.org/10.1016/S1474-4422(18)30499-X

doi: 10.1016/S1474-4422(18)30499-X

Feng X, Luo D, Wei G et al (2021) Non-coding RNAs: the key regulators in NLRP3 inflammasome-mediated inflammatory diseases. Int Immunopharmacol 100:108105. https://doi.org/10.1016/j.intimp.2021.108105

doi: 10.1016/j.intimp.2021.108105 pubmed: 34481143

Fernandes JCR, Acuña SM, Aoki JI et al (2019) Long non-coding RNAs in the regulation of gene expression: physiology and disease. Non-coding RNA 5(1):17. https://doi.org/10.3390/ncrna5010017

doi: 10.3390/ncrna5010017 pubmed: 30781588 pmcid: 6468922

Fischer A, Sananbenesi F, Wang X et al (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature 447:178–182. https://doi.org/10.1038/nature05772

doi: 10.1038/nature05772 pubmed: 17468743

Flynn RA, Chang HY (2014) Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell 14:752–761. https://doi.org/10.1016/j.stem.2014.05.014

doi: 10.1016/j.stem.2014.05.014 pubmed: 24905165 pmcid: 4120821

Freeman L, Guo H, David CN et al (2017) NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med 214:1351–1370. https://doi.org/10.1084/jem.20150237

doi: 10.1084/jem.20150237 pubmed: 28404595 pmcid: 5413320

Freeman LC, Ting JPY (2016) The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem 136:29–38. https://doi.org/10.1111/jnc.13217

doi: 10.1111/jnc.13217 pubmed: 26119245

Fu Y, Chen J, Li YJ et al (2013) Antioxidant and anti-inflammatory activities of six flavonoids separated from licorice. Food Chem 141:1063–1071. https://doi.org/10.1016/j.foodchem.2013.03.089

doi: 10.1016/j.foodchem.2013.03.089 pubmed: 23790887

Gaidt MM, Ebert TS, Chauhan D et al (2016) Human Monocytes Engage an Alternative Inflammasome Pathway. Immunity 44:833–846. https://doi.org/10.1016/j.immuni.2016.01.012

doi: 10.1016/j.immuni.2016.01.012 pubmed: 27037191

Gao Y, Yu S, Chen M et al (2023) cFLIPS regulates alternative NLRP3 inflammasome activation in human monocytes. Cell Mol Immunol 20(10):1203–1215. https://doi.org/10.1038/s41423-023-01077-y

doi: 10.1038/s41423-023-01077-y pubmed: 37591930

Gattorno M, Tassi S, Carta S et al (2007) Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 56:3138–3148. https://doi.org/10.1002/art.22842

doi: 10.1002/art.22842 pubmed: 17763411

Ge X, Li W, Huang S et al (2018) The pathological role of NLRs and AIM2 inflammasome-mediated pyroptosis in damaged blood-brain barrier after traumatic brain injury. Brain Res 1697:10–20. https://doi.org/10.1016/j.brainres.2018.06.008

doi: 10.1016/j.brainres.2018.06.008 pubmed: 29886252

Gonzalez-Zuñiga M, Contreras PS, Estrada LD et al (2014) C-abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in alzheimer’s disease. Mol Cell 56:163–173. https://doi.org/10.1016/j.molcel.2014.08.013

doi: 10.1016/j.molcel.2014.08.013 pubmed: 25219501

Gordon R, Albornoz EA, Christie DC et al (2018) Inflammasome inhibition prevents -synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med 10:1–13. https://doi.org/10.1126/scitranslmed.aah4066

doi: 10.1126/scitranslmed.aah4066

Govindula A, Ranadive N, Nampoothiri M et al (2023) Emphasizing the Crosstalk Between Inflammatory and Neural Signaling in Post-traumatic Stress Disorder (PTSD). J Neuroimmune Pharmacol. https://doi.org/10.1007/s11481-023-10064-z

doi: 10.1007/s11481-023-10064-z pubmed: 37097603 pmcid: 10577110

Greenberg MVC, Bourc’his D, (2019) The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol 20:590–607. https://doi.org/10.1038/s41580-019-0159-6

doi: 10.1038/s41580-019-0159-6 pubmed: 31399642

Gritsenko A, Yu S, Martin-Sanchez F et al (2020) Priming is dispensable for NLRP3 inflammasome activation in human monocytes in vitro. Front Immunol 11:565924. https://doi.org/10.3389/fimmu.2020.565924

doi: 10.3389/fimmu.2020.565924 pubmed: 33101286 pmcid: 7555430

Groß CJ, Mishra R, Schneider KS et al (2016) K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria. Immunity 45:761–773. https://doi.org/10.1016/j.immuni.2016.08.010

doi: 10.1016/j.immuni.2016.08.010 pubmed: 27692612

Guan JS, Haggarty SJ, Giacometti E et al (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459:55–60. https://doi.org/10.1038/nature07925

doi: 10.1038/nature07925 pubmed: 19424149 pmcid: 3498958

Guan Y, Han F (2020) Key mechanisms and potential targets of the NLRP3 inflammasome in neurodegenerative diseases. Front Integr Neurosci 14:1–9. https://doi.org/10.3389/fnint.2020.00037

doi: 10.3389/fnint.2020.00037

Guo C, Fulp JW, Jiang Y et al (2017) Development and characterization of a hydroxyl-sulfonamide analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chem Neurosci 8:2194–2201. https://doi.org/10.1021/acschemneuro.7b00124

doi: 10.1021/acschemneuro.7b00124 pubmed: 28653829

Guo YJ, Ren J, Liu H et al (2022) Effects of MCC950 on nerve injury in rats with intracerebral hemorrhage. Zhongguo Ying Yong Sheng Li Xue Za Zhi 38(1):11–16. https://doi.org/10.12047/j.cjap.6191.2022.003

doi: 10.12047/j.cjap.6191.2022.003 pubmed: 35634663

Han C, Guo L, Yang Y et al (2020) Mechanism of microRNA-22 in regulating neuroinflammation in Alzheimer’s disease. Brain Behav 10(6):e01627. https://doi.org/10.1002/brb3.1627

doi: 10.1002/brb3.1627 pubmed: 32307887 pmcid: 7303389

Han KM, Choi KW, Kim A et al (2022) Association of DNA methylation of the NLRP3 gene with changes in cortical thickness in major depressive disorder. Int J Mol Sci 23(10):5768. https://doi.org/10.3390/ijms23105768

doi: 10.3390/ijms23105768 pubmed: 35628578 pmcid: 9143533

Han Y, Qiu H, Pei X et al (2018) Low-dose sinapic acid abates the Pyroptosis of macrophages by downregulation of lncRNA-MALAT1 in rats with diabetic atherosclerosis. J Cardiovasc Pharmacol 71:104–112. https://doi.org/10.1097/FJC.0000000000000550

doi: 10.1097/FJC.0000000000000550 pubmed: 29095793

Haque ME, Akther M, Jakaria M et al (2020) Targeting the microglial NLRP3 inflammasome and its role in Parkinson’s disease. Mov Disord 35:20–33. https://doi.org/10.1002/mds.27874

doi: 10.1002/mds.27874 pubmed: 31680318

He H, Jiang H, Chen Y et al (2018) Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 9:1–12. https://doi.org/10.1038/s41467-018-04947-6

doi: 10.1038/s41467-018-04947-6

He Y, Hara H, Núñez G (2016a) Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 41:1012–1021. https://doi.org/10.1016/j.tibs.2016.09.002

doi: 10.1016/j.tibs.2016.09.002 pubmed: 27669650 pmcid: 5123939

He Y, Varadarajan S, Muñoz-Planillo R et al (2014) 3,4-Methylenedioxy-β’-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem 289:1142–1150. https://doi.org/10.1074/jbc.M113.515080

doi: 10.1074/jbc.M113.515080 pubmed: 24265316

He Y, Zeng MY, Yang D et al (2016b) NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530:354–357. https://doi.org/10.1038/nature16959

doi: 10.1038/nature16959 pubmed: 26814970 pmcid: 4810788

Herman FJ, Pasinetti GM (2018) Principles of inflammasome priming and inhibition: Implications for psychiatric disorders. Brain Behav Immun 73:66–84. https://doi.org/10.1016/j.bbi.2018.06.010

doi: 10.1016/j.bbi.2018.06.010 pubmed: 29902514 pmcid: 6526722

Hochheiser IV, Pilsl M, Hagelueken G et al (2022) Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature 604:184–189. https://doi.org/10.1038/s41586-022-04467-w

doi: 10.1038/s41586-022-04467-w pubmed: 35114687

Holley CL, Schroder K (2020) The rOX-stars of inflammation: links between the inflammasome and mitochondrial meltdown. Clin Transl Immunol 9(2):e01109. https://doi.org/10.1002/cti2.1109

doi: 10.1002/cti2.1109

Hong H, Kim BS, Im HI (2016) Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurourol J 20:S2–S7. https://doi.org/10.5213/inj.1632604.302

doi: 10.5213/inj.1632604.302 pubmed: 27230456 pmcid: 4895907

Hong P, Gu RN, Li FX et al (2019) NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes. J Neuroinflammation 16:1–13. https://doi.org/10.1186/s12974-019-1498-0

doi: 10.1186/s12974-019-1498-0

Hu L, Zhang H, Wang B et al (2020) MicroRNA-152 attenuates neuroinflammation in intracerebral hemorrhage by inhibiting thioredoxin-interacting protein (TXNIP)-mediated NLRP3 inflammasome activation. Int Immunopharmacol 80:106141. https://doi.org/10.1016/j.intimp.2019.106141

doi: 10.1016/j.intimp.2019.106141 pubmed: 31982825

Huang J, Wu L, Tashiro SI et al (2005) A comparison of the signal pathways between the TNFα- and oridonin-induced murine L929 fibrosarcoma cell death. Acta Med Okayama 59(6):261–270. https://doi.org/10.18926/AMO/31960

doi: 10.18926/AMO/31960 pubmed: 16418769

Huang Y, Jiang H, Chen Y et al (2018) Tranilast directly targets NLRP 3 to treat inflammasome-driven diseases. EMBO Mol Med 10(4):e8689. https://doi.org/10.15252/emmm.201708689

doi: 10.15252/emmm.201708689 pubmed: 29531021 pmcid: 5887903

Huang Y, Xu W, Zhou R (2021) NLRP3 inflammasome activation and cell death. Cell Mol Immunol 18:2114–2127. https://doi.org/10.1038/s41423-021-00740-6

doi: 10.1038/s41423-021-00740-6 pubmed: 34321623 pmcid: 8429580

Hughes FM, Sexton SJ, Jin H et al (2017) Bladder fibrosis during outlet obstruction is triggered through the NLRP3 inflammasome and the production of IL-1β. Am J Physiol - Ren Physiol 313:F603–F610. https://doi.org/10.1152/ajprenal.00128.2017

doi: 10.1152/ajprenal.00128.2017

Hughes FM, Sexton SJ, Ledig PD et al (2019) Bladder decompensation and reduction in nerve density in a rat model of chronic bladder outlet obstruction are attenuated with the NLRP3 inhibitor glyburide. Am J Physiol - Ren Physiol 316:F113–F120. https://doi.org/10.1152/ajprenal.00400.2018

doi: 10.1152/ajprenal.00400.2018

Hung WL, Ho CT, Pan MH (2020) Targeting the NLRP3 Inflammasome in Neuroinflammation: Health Promoting Effects of Dietary Phytochemicals in Neurological Disorders. Mol Nutr Food Res 64:1–22. https://doi.org/10.1002/mnfr.201900550

doi: 10.1002/mnfr.201900550

Irrera N, Pizzino G, Calò M et al (2017a) Lack of the Nlrp3 inflammasome improves mice recovery following traumatic brain injury. Front Pharmacol 8:459. https://doi.org/10.3389/fphar.2017.00459

doi: 10.3389/fphar.2017.00459 pubmed: 28769794 pmcid: 5509758

Irrera N, Vaccaro M, Bitto A et al (2017b) BAY 11–7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clin Sci 131:487–498. https://doi.org/10.1042/CS20160645

doi: 10.1042/CS20160645

Ising C, Venegas C, Zhang S et al (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575:669–673. https://doi.org/10.1038/s41586-019-1769-z

doi: 10.1038/s41586-019-1769-z pubmed: 31748742 pmcid: 7324015

Ismael S, Nasoohi S, Ishrat T (2018) MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury. J Neurotrauma 35:1294–1303. https://doi.org/10.1089/neu.2017.5344

doi: 10.1089/neu.2017.5344 pubmed: 29295651 pmcid: 5962912

Ito M, Shichita T, Okada M et al (2015) Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun 6:1–11. https://doi.org/10.1038/ncomms8360

doi: 10.1038/ncomms8360

Iyer SS, He Q, Janczy JR et al (2013) Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 39:311–323. https://doi.org/10.1016/j.immuni.2013.08.001

doi: 10.1016/j.immuni.2013.08.001 pubmed: 23954133 pmcid: 3779285

Jéru I, Marlin S, Le Borgne G et al (2010) Functional consequences of a germline mutation in the leucine-rich repeat domain of NLRP3 Identified in an atypical autoinflammatory disorder. Arthritis Rheum 62:1176–1185. https://doi.org/10.1002/art.27326

doi: 10.1002/art.27326 pubmed: 20131254

Jiang H, He H, Chen Y et al (2017) Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 214:3219–3238. https://doi.org/10.1084/jem.20171419

doi: 10.1084/jem.20171419 pubmed: 29021150 pmcid: 5679172

Jiang S, Cheng SJ, Ren LC et al (2019) An expanded landscape of human long noncoding RNA. Nucleic Acids Res 47:7842–7856. https://doi.org/10.1093/nar/gkz621

doi: 10.1093/nar/gkz621 pubmed: 31350901 pmcid: 6735957

Jiang X, Yang F, Ou D et al (2022) MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure. Bioengineered 13:8593–8604. https://doi.org/10.1080/21655979.2022.2053813

doi: 10.1080/21655979.2022.2053813 pubmed: 35287557 pmcid: 9162026

Jo EK, Kim JK, Shin DM, Sasakawa C (2016) Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 13:148–159. https://doi.org/10.1038/cmi.2015.95

doi: 10.1038/cmi.2015.95 pubmed: 26549800

Juliana C, Fernandes-Alnemri T, Wu J et al (2010) Anti-inflammatory compounds parthenolide and bay 11–7082 are direct inhibitors of the inflammasome. J Biol Chem 285:9792–9802. https://doi.org/10.1074/jbc.M109.082305

doi: 10.1074/jbc.M109.082305 pubmed: 20093358 pmcid: 2843228

Junn E, Lee KW, Byeong SJ et al (2009) Repression of α-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 106:13052–13057. https://doi.org/10.1073/pnas.0906277106

doi: 10.1073/pnas.0906277106 pubmed: 19628698 pmcid: 2722353

Kaikkonen MU, Lam MTY, Glass CK (2011) Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res 90:430–440. https://doi.org/10.1093/cvr/cvr097

doi: 10.1093/cvr/cvr097 pubmed: 21558279 pmcid: 3096308

Kajitani N, Iwata M, Miura A et al (2020) Prefrontal cortex infusion of beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, produces antidepressant-like effects in a rodent model of depression. Neuropsychopharmacol Reports 40:157–165. https://doi.org/10.1002/npr2.12099

doi: 10.1002/npr2.12099

Kang L, Long X, Wang J, Lv J (2022) miR-122-5p attenuates the inflammatory response by modulating microglia polarization after traumatic brain injury. Chinese J Emerg Med 31:1077–1084. https://doi.org/10.3760/cma.j.issn.1671-0282.2022.08.011

doi: 10.3760/cma.j.issn.1671-0282.2022.08.011

Kanneganti A, Malireddi RKS, Saavedra PHV et al (2018) GSD MD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever. J Exp Med 215:1519–1529. https://doi.org/10.1084/jem.20172060

doi: 10.1084/jem.20172060 pubmed: 29793924 pmcid: 5987922

Kaufmann FN, Costa AP, Ghisleni G et al (2017) NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. Brain Behav Immun 64:367–383. https://doi.org/10.1016/j.bbi.2017.03.002

doi: 10.1016/j.bbi.2017.03.002 pubmed: 28263786

Kelley N, Jeltema D, Duan Y, He Y (2019) The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int J Mol Sci 20:1–24. https://doi.org/10.3390/ijms20133328

doi: 10.3390/ijms20133328

Khare S, Ratsimandresy RA, De Almeida L et al (2014) The PYRIN domain-only protein POP3 inhibits ALR inflammasomes and regulates responses to infection with DNA viruses. Nat Immunol 15:343–353. https://doi.org/10.1038/ni.2829

doi: 10.1038/ni.2829 pubmed: 24531343 pmcid: 4123781

Kim BH, Min YS, Choi JS et al (2011) Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling. Exp Mol Med 43:313–321. https://doi.org/10.3858/emm.2011.43.5.035

doi: 10.3858/emm.2011.43.5.035 pubmed: 21499010 pmcid: 3104254

Kim BH, Yoon BR, Kim EK et al (2016a) Alleviation of collagen-induced arthritis by the benzoxathiole derivative BOT-4-one in mice: Implication of the Th1- and Th17-cell-mediated immune responses. Biochem Pharmacol 110–111:47–57. https://doi.org/10.1016/j.bcp.2016.03.018

doi: 10.1016/j.bcp.2016.03.018 pubmed: 27005941

Kim MM, Parmar H, Cao Y et al (2016b) Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A tite-crm phase I/II clinical trial. Transl Oncol 9:108–113. https://doi.org/10.1016/j.tranon.2015.12.003

doi: 10.1016/j.tranon.2015.12.003 pubmed: 27084426 pmcid: 4833892

Kip E, Parr-Brownlie LC (2023) Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. Front Neurosci 17:1092537. https://doi.org/10.3389/fnins.2023.1092537

doi: 10.3389/fnins.2023.1092537 pubmed: 36875655 pmcid: 9975355

Kolati SR, Kasala ER, Bodduluru LN et al (2015) BAY 11–7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway. Environ Toxicol Pharmacol 39:690–699. https://doi.org/10.1016/j.etap.2015.01.019

doi: 10.1016/j.etap.2015.01.019 pubmed: 25704036

Konneh M (1998) Tranilast Kissei Pharmaceutical. IDrugs 1(1):141–146

pubmed: 18465519

Kumar S, Gonzalez EA, Rameshwar P, Etchegaray JP (2020) Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers (Basel) 12:1–32. https://doi.org/10.3390/cancers12123657

doi: 10.3390/cancers12123657

La Rosa F, Mancuso R, Agostini S et al (2021) Pharmacological and epigenetic regulators of nlrp3 inflammasome activation in alzheimer’s disease. Pharmaceuticals 14(11):1187. https://doi.org/10.3390/ph14111187

doi: 10.3390/ph14111187 pubmed: 34832969 pmcid: 8623160

Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161. https://doi.org/10.1146/annurev-cellbio-101011-155745

doi: 10.1146/annurev-cellbio-101011-155745 pubmed: 22974247

Lamkanfi M, Mueller JL, Vitari AC et al (2009) Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 187:61–70. https://doi.org/10.1083/jcb.200903124

doi: 10.1083/jcb.200903124 pubmed: 19805629 pmcid: 2762099

Lang Y, Chu F, Liu L et al (2022) Potential role of BAY11-7082, a NF-κB blocker inhibiting experimental autoimmune encephalomyelitis in C57BL/6J mice via declining NLRP3 inflammasomes. Clin Exp Immunol 207:378–386. https://doi.org/10.1093/cei/uxab022

doi: 10.1093/cei/uxab022 pubmed: 35553640

Lara-Reyna S, Caseley EA, Topping J et al (2022) Inflammasome activation: from molecular mechanisms to autoinflammation. Clin Transl Immunol 11(7):e1404. https://doi.org/10.1002/cti2.1404

doi: 10.1002/cti2.1404

Lechtenberg BC, Mace PD, Riedl SJ (2014) Structural mechanisms in NLR inflammasome signaling. Curr Opin Struct Biol 29:17–25. https://doi.org/10.1016/j.sbi.2014.08.011

doi: 10.1016/j.sbi.2014.08.011 pubmed: 25201319

Lee HG, Cho NC, Jeong AJ et al (2016) Immunomodulatory activities of the benzoxathiole derivative BOT-4-one ameliorate pathogenic skin inflammation in mice. J Invest Dermatol 136:107–116. https://doi.org/10.1038/JID.2015.384

doi: 10.1038/JID.2015.384 pubmed: 26763430

Li C, Chen M, He X, Ouyang D (2021a) A mini-review on ion fluxes that regulate NLRP3 inflammasome activation. Acta Biochim Biophys Sin (Shanghai) 53:131–139. https://doi.org/10.1093/abbs/gmaa155

doi: 10.1093/abbs/gmaa155 pubmed: 33355638

Li D, Yang H, Ma J et al (2018) MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson’s disease by targeting Nlrp3. Hum Cell 31:106–115. https://doi.org/10.1007/s13577-017-0187-5

doi: 10.1007/s13577-017-0187-5 pubmed: 29274035

Li G, Zong X, Cheng Y et al (2022a) miR-223-3p contributes to suppressing NLRP3 inflammasome activation in Streptococcus equi ssp. zooepidemicus infection. Vet Microbiol 269:109430. https://doi.org/10.1016/j.vetmic.2022.109430

doi: 10.1016/j.vetmic.2022.109430 pubmed: 35427992

Li JM, Hu T, Zhou XN et al (2023) The involvement of NLRP3 inflammasome in CUMS-induced AD-like pathological changes and related cognitive decline in mice. J Neuroinflammation 20(1):112. https://doi.org/10.1186/s12974-023-02791-0

doi: 10.1186/s12974-023-02791-0 pubmed: 37165444 pmcid: 10173607

Li Q, Feng H, Wang H et al (2022b) Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction. EMBO Rep 23(2):e53499. https://doi.org/10.15252/embr.202153499

doi: 10.15252/embr.202153499 pubmed: 34882936

Li S, Fang Y, Zhang Y et al (2022c) Microglial NLRP3 inflammasome activates neurotoxic astrocytes in depression-like mice. Cell Rep 41(4):111532. https://doi.org/10.1016/j.celrep.2022.111532

doi: 10.1016/j.celrep.2022.111532 pubmed: 36288697

Li Y, Niu X, Xu H, Li Q, Meng L, He M, Zhang J, Zhang Z, Zhang Z (2020) VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis. Exp Cell Res 389(1):111847. https://doi.org/10.1016/j.yexcr.2020.111847

doi: 10.1016/j.yexcr.2020.111847 pubmed: 31972218

Li Y, Song W, Tong Y et al (2021b) Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a/SYK/NF-κB axis. J Neuroinflammation 18(1):1. https://doi.org/10.1186/s12974-020-02040-8

doi: 10.1186/s12974-020-02040-8 pubmed: 33402173 pmcid: 7786465

Liang Y, Song P, Chen W et al (2021) Inhibition of caspase-1 ameliorates ischemia-associated blood-brain barrier dysfunction and integrity by suppressing pyroptosis activation. Front Cell Neurosci 14:540669. https://doi.org/10.3389/fncel.2020.540669

doi: 10.3389/fncel.2020.540669 pubmed: 33584203 pmcid: 7874210

Liao J, Kapadia VS, Brown LS et al (2015) The NLRP3 inflammasome is critically involved in the development of bronchopulmonary dysplasia. Nat Commun 6:1–12. https://doi.org/10.1038/ncomms9977

doi: 10.1038/ncomms9977

Liu CC, Huang ZX, Li X et al (2018) Upregulation of NLRP3 via STAT3-dependent histone acetylation contributes to painful neuropathy induced by bortezomib. Exp Neurol 302:104–111. https://doi.org/10.1016/j.expneurol.2018.01.011

doi: 10.1016/j.expneurol.2018.01.011 pubmed: 29339053

Liu D, Tang H, Li XY et al (2017a) Targeting the HDAC2/HNF-4A/miR-101b/AMPK pathway rescues tauopathy and dendritic abnormalities in alzheimer’s disease. Mol Ther 25:752–764. https://doi.org/10.1016/j.ymthe.2017.01.018

doi: 10.1016/j.ymthe.2017.01.018 pubmed: 28202389 pmcid: 5363202

Liu H, Xu Y, Liang K, Liu R (2020) Immune cells combined with NLRP3 inflammasome inhibitor exert better antitumor effect on pancreatic ductal adenocarcinoma. Front Oncol 10:1378. https://doi.org/10.3389/fonc.2020.01378

doi: 10.3389/fonc.2020.01378 pubmed: 32974137 pmcid: 7471723

Liu L, Dong Y, Ye M et al (2017b) The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. J Crohns Colitis 11:737–750. https://doi.org/10.1093/ecco-jcc/jjw219

doi: 10.1093/ecco-jcc/jjw219 pubmed: 27993998 pmcid: 5881697

Liu L, Wang D, Liu M et al (2022) The development from hyperuricemia to gout: key mechanisms and natural products for treatment. Acupunct Herb Med 2:25–32. https://doi.org/10.1097/hm9.0000000000000016

doi: 10.1097/hm9.0000000000000016

Liu X, Pichulik T, Wolz OO et al (2017c) Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol 140:1054-1067.e10. https://doi.org/10.1016/j.jaci.2017.01.017

doi: 10.1016/j.jaci.2017.01.017 pubmed: 28216434

Liu X, Xu J, Zhou J, Shen Q (2021) Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes Dis 8:448–462. https://doi.org/10.1016/j.gendis.2020.06.010

doi: 10.1016/j.gendis.2020.06.010 pubmed: 34179309

Liu X, Zhang Z, Ruan J et al (2016) Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535:153–158. https://doi.org/10.1038/nature18629

doi: 10.1038/nature18629 pubmed: 27383986 pmcid: 5539988

Long J, Wang Q, He H et al (2019) NLRP3 inflammasome activation is involved in trimethyltin-induced neuroinflammation. Brain Res 1718:186–193. https://doi.org/10.1016/j.brainres.2019.05.003

doi: 10.1016/j.brainres.2019.05.003 pubmed: 31059678

Lonnemann N, Hosseini S, Marchetti C et al (2020) The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 117:32145–32154. https://doi.org/10.1073/pnas.2009680117

doi: 10.1073/pnas.2009680117 pubmed: 33257576 pmcid: 7749353

Lowes DJ, Hevener KE, Peters BM (2020) Second-generation antidiabetic sulfonylureas inhibit candida albicans and candidalysin-mediated activation of the NLRP3 inflammasome. Antimicrob Agents Chemother 64(2):e01777-19. https://doi.org/10.1128/AAC.01777-19

doi: 10.1128/AAC.01777-19 pubmed: 31712208 pmcid: 6985747

Lu W, Karuppagounder SS, Springer DA et al (2016) A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell 165:1672–1685

doi: 10.1016/j.cell.2016.05.075

Luo J, Jiang N, Chen J et al (2022a) Inhibition of miR-423-5p exerts neuroprotective effects in an experimental rat model of cerebral ischemia/reperfusion injury. Neuroscience 503:95–106. https://doi.org/10.1016/j.neuroscience.2022.08.024

doi: 10.1016/j.neuroscience.2022.08.024 pubmed: 36067951

Luo S, Yang M, Han Y et al (2022b) β-Hydroxybutyrate against cisplatin-induced acute kidney injury via inhibiting NLRP3 inflammasome and oxidative stress. Int Immunopharmacol 111:109101. https://doi.org/10.1016/j.intimp.2022.109101

doi: 10.1016/j.intimp.2022.109101 pubmed: 35940076

Luo Y, Lu J, Ruan W et al (2019) MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats. Brain Res Bull 146:320–326. https://doi.org/10.1016/j.brainresbull.2019.01.027

doi: 10.1016/j.brainresbull.2019.01.027 pubmed: 30716395

Lee MN, Lee Y, Wu D, Pae M (2021) Luteolin inhibits NLRP3 inflammasome activation via blocking ASC oligomerization. J Nutr Biochem 92:108614. https://doi.org/10.1016/j.jnutbio.2021.108614

doi: 10.1016/j.jnutbio.2021.108614 pubmed: 33705947

Platten M, Ho PP, Youssef S et al (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310(5749):850–855. https://doi.org/10.1126/science.1117634

doi: 10.1126/science.1117634 pubmed: 16272121

Ma Z, Hu C, Zhang Y (2011) Therapeutic effect of rabdosia rubescens aqueous extract on chronic pharyngitis and its safty. J Cent South Univ Medical Sci 36:170–173. https://doi.org/10.3969/j.issn.1672-7347.2011.02.014

doi: 10.3969/j.issn.1672-7347.2011.02.014

Mamik MK, Power C (2017) Inflammasomes in neurological diseases: Emerging pathogenic and therapeutic concepts. Brain 140:2273–2285. https://doi.org/10.1093/brain/awx133

doi: 10.1093/brain/awx133 pubmed: 29050380

Mangan MSJ, Olhava EJ, Roush WR et al (2018) Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 17:588–606. https://doi.org/10.1038/nrd.2018.97

doi: 10.1038/nrd.2018.97 pubmed: 30026524

Marchetti C, Swartzwelter B, Gamboni F et al (2018a) OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA 115(7):E1530–E1539. https://doi.org/10.1073/pnas.1716095115

doi: 10.1073/pnas.1716095115 pubmed: 29378952 pmcid: 5816172

Marchetti C, Swartzwelter B, Koenders MI et al (2018b) NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther 20. https://doi.org/10.1186/s13075-018-1664-2

Martin BN, Wang C, Li X (2016) T cell-intrinsic ASC critically promotes Th17-mediated experimental autoimmune encephalomyelitis. J Immunol 196:189.5-189.5. https://doi.org/10.4049/jimmunol.196.supp.189.5

doi: 10.4049/jimmunol.196.supp.189.5

Martinez R, Schackert G, Esteller M (2007) Hypermethylation of the proapoptotic gene TMS1/ASC: Prognostic importance in glioblastoma multiforme. J Neurooncol 82:133–139. https://doi.org/10.1007/s11060-006-9264-4

doi: 10.1007/s11060-006-9264-4 pubmed: 17048097

Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668. https://doi.org/10.1146/annurev.immunol.25.022106.141627

doi: 10.1146/annurev.immunol.25.022106.141627 pubmed: 19302049 pmcid: 2996236

Mathy NW, Chen XM (2017) Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem 292:12375–12382. https://doi.org/10.1074/jbc.R116.760884

doi: 10.1074/jbc.R116.760884 pubmed: 28615453 pmcid: 5535013

Meng G, Zhang F, Fuss I et al (2009) A Mutation in the Nlrp3 Gene Causing Inflammasome Hyperactivation Potentiates Th17 Cell-Dominant Immune Responses. Immunity 30:860–874. https://doi.org/10.1016/j.immuni.2009.04.012

doi: 10.1016/j.immuni.2009.04.012 pubmed: 19501001 pmcid: 2764254

Menon MP, Hua KF (2020) The long non-coding RNAs: paramount regulators of the NLRP3 inflammasome. Front Immunol 11:569524. https://doi.org/10.3389/fimmu.2020.569524

doi: 10.3389/fimmu.2020.569524 pubmed: 33101288 pmcid: 7546312

Moretti J, Blander JM (2021) Increasing complexity of NLRP3 inflammasome regulation. J Leukoc Biol 109:561–571. https://doi.org/10.1002/JLB.3MR0520-104RR

doi: 10.1002/JLB.3MR0520-104RR pubmed: 32531835

Morgensztern D, Rose M, Waqar SN et al (2019) RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br J Cancer 121:211–217. https://doi.org/10.1038/s41416-019-0504-8

doi: 10.1038/s41416-019-0504-8 pubmed: 31231122 pmcid: 6738071

Mosayebian A, Sherkat R, Abediankenari S et al (2021) Dimethylaminoparthenolide (DMAPT) as an alternative approach for treatment of Familial Mediterranean Fever (FMF). Iran J Basic Med Sci 24:1421–1427. https://doi.org/10.22038/ijbms.2021.59180.13140

doi: 10.22038/ijbms.2021.59180.13140 pubmed: 35096301 pmcid: 8769508

Murakami T, Ockinger J, Yu J et al (2012) Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci USA 109:11282–11287. https://doi.org/10.1073/pnas.1117765109

doi: 10.1073/pnas.1117765109 pubmed: 22733741 pmcid: 3396518

Nakahira K, Haspel JA, Rathinam VAK et al (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12:222–230. https://doi.org/10.1038/ni.1980

doi: 10.1038/ni.1980 pubmed: 21151103

Nassar A, Kodi T, Satarker S et al (2022) Astrocytic microRNAs and transcription factors in Alzheimer’s disease and therapeutic interventions. Cells 11(24):4111. https://doi.org/10.3390/cells11244111

doi: 10.3390/cells11244111 pubmed: 36552875 pmcid: 9776935

Naz Villalba E, Gomez de la Fuente E, Caro Gutierrez D et al (2016) Muckle-Wells Syndrome: A Case Report with an NLRP3 T348M Mutation. Pediatr Dermatol 33:e311–e314. https://doi.org/10.1111/pde.12905

doi: 10.1111/pde.12905 pubmed: 27435956

Neuwirt E, Gorka O, Saller BS et al (2021) NLRP3 as a sensor of metabolism gone awry. Curr Opin Biotechnol 68:300–309. https://doi.org/10.1016/j.copbio.2021.03.009

doi: 10.1016/j.copbio.2021.03.009 pubmed: 33862489

Oizumi T, Mayanagi T, Toya Y et al (2022) NLRP3 Inflammasome Inhibitor OLT1177 Suppresses Onset of Inflammation in Mice with Dextran Sulfate Sodium-Induced Colitis. Dig Dis Sci 67:2912–2921. https://doi.org/10.1007/s10620-021-07184-y

doi: 10.1007/s10620-021-07184-y pubmed: 34345943

Onizawa Y, Katoh T, Miura R et al (2022) Acetoacetate is a trigger of NLRP3 inflammasome activation in bovine peripheral blood mononuclear cells. Vet Immunol Immunopathol 244:110370. https://doi.org/10.1016/j.vetimm.2021.110370

doi: 10.1016/j.vetimm.2021.110370 pubmed: 34952251

Oronsky B, Paulmurugan R, Foygel K et al (2017) RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs 26:109–119. https://doi.org/10.1080/13543784.2017.1268600

doi: 10.1080/13543784.2017.1268600 pubmed: 27935336

Østergaard JA, Jha JC, Sharma A et al (2022) Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease. Clin Sci 136:167–180. https://doi.org/10.1042/CS20210865

doi: 10.1042/CS20210865

Pan Z, Shan Q, Gu P et al (2018) miRNA-23a/CXCR4 regulates neuropathic pain via directly targeting TXNIP/NLRP3 inflammasome axis. J Neuroinflammation 15(1):29. https://doi.org/10.1186/s12974-018-1073-0

doi: 10.1186/s12974-018-1073-0 pubmed: 29386025 pmcid: 5791181

Park S, Juliana C, Hong S et al (2013) The Mitochondrial Antiviral Protein MAVS Associates with NLRP3 and Regulates Its Inflammasome Activity. J Immunol 191:4358–4366. https://doi.org/10.4049/jimmunol.1301170

doi: 10.4049/jimmunol.1301170 pubmed: 24048902

Patel D, Gaikwad S, Challagundla N et al (2018) Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis. Int Immunopharmacol 54:375–384. https://doi.org/10.1016/j.intimp.2017.11.026

doi: 10.1016/j.intimp.2017.11.026 pubmed: 29202301

Pellegrini C, Fornai M, Antonioli L et al (2019) Phytochemicals as novel therapeutic strategies for nlrp3 inflammasome-related neurological, metabolic, and inflammatory diseases. Int J Mol Sci 20:1–31. https://doi.org/10.3390/ijms20122876

doi: 10.3390/ijms20122876

Peng W, Zhang B, Sun Z et al (2021) Targeting the Nod-like receptor protein 3 Inflammasome with inhibitor MCC950 rescues lipopolysaccharide-induced inhibition of osteogenesis in Human periodontal ligament cells. Arch Oral Biol 131:105269. https://doi.org/10.1016/j.archoralbio.2021.105269

doi: 10.1016/j.archoralbio.2021.105269 pubmed: 34601319

Pike AF, Longhena F, Faustini G et al (2022) Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease. J Neuroinflammation 19(1):50. https://doi.org/10.1186/s12974-022-02410-4

doi: 10.1186/s12974-022-02410-4 pubmed: 35172843 pmcid: 8848816

Poli G, Fabi C, Bellet MM et al (2020) Epigenetic mechanisms of inflammasome regulation. Int J Mol Sci 21:1–15. https://doi.org/10.3390/ijms21165758

doi: 10.3390/ijms21165758

Porter KA, Duffy EB, Nyland P et al (2014) The CLRX.1/NOD24 (NLRP2P) pseudogene codes a functional negative regulator of NF-κB, pyrin-only protein 4. Genes Immun 15:392–403. https://doi.org/10.1038/gene.2014.30

doi: 10.1038/gene.2014.30 pubmed: 24871464 pmcid: 4311403

Poudel B, Gurung P (2018) An update on cell intrinsic negative regulators of the NLRP3 inflammasome. J Leukoc Biol 103:1165–1177. https://doi.org/10.1002/JLB.3MIR0917-350R

doi: 10.1002/JLB.3MIR0917-350R

Próchnicki T, Mangan MS, Latz E (2016) Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation [version 1; referees: 2 approved]. F1000Research 5:1–15. https://doi.org/10.12688/F1000RESEARCH.8614.1

doi: 10.12688/F1000RESEARCH.8614.1

Qiao J, Wu X, Luo Q et al (2018) NLRP3 regulates platelet integrin ±IIbβ3 outside-in signaling, hemostasis and arterial thrombosis. Haematologica 103(9):1568–1576. https://doi.org/10.3324/haematol.2018.191700

doi: 10.3324/haematol.2018.191700 pubmed: 29794149 pmcid: 6119128

Raneros AB, Bernet CR, Flórez AB, Suarez-Alvarez B (2021) An epigenetic insight into NLRP3 inflammasome activation in inflammation-related processes. Biomedicines 9(11):1614. https://doi.org/10.3390/biomedicines9111614

doi: 10.3390/biomedicines9111614 pubmed: 34829842 pmcid: 8615487

Ratsimandresy RA, Chu LH, Khare S et al (2017) The PYRIN domain-only protein POP2 inhibits inflammasome priming and activation. Nat Commun 8:1–15. https://doi.org/10.1038/ncomms15556

doi: 10.1038/ncomms15556

Reid T, Oronsky B, Scicinski J et al (2015) Safety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol 16:1133–1142. https://doi.org/10.1016/S1470-2045(15)00089-3

doi: 10.1016/S1470-2045(15)00089-3 pubmed: 26296952

Ren Y, Wang Q, Yang Z et al (2022) MCC950 ameliorates the dementia symptom at the early age of line M83 mouse and reduces hippocampal α-synuclein accumulation. Biochem Biophys Res Commun 611:23–30. https://doi.org/10.1016/j.bbrc.2022.04.076

doi: 10.1016/j.bbrc.2022.04.076 pubmed: 35472607

Saadane A, Masters S, DiDonato J et al (2007) Parthenolide inhibits IκB kinase, NF-κB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol 36:728–736. https://doi.org/10.1165/rcmb.2006-0323OC

doi: 10.1165/rcmb.2006-0323OC pubmed: 17272824 pmcid: 1899341

Saber S, Youssef ME, Sharaf H et al (2021) BBG enhances OLT1177-induced NLRP3 inflammasome inactivation by targeting P2X7R/NLRP3 and MyD88/NF-κB signaling in DSS-induced colitis in rats. Life Sci 270:119123. https://doi.org/10.1016/j.lfs.2021.119123

doi: 10.1016/j.lfs.2021.119123 pubmed: 33548287

Saeedi-Boroujeni A, Mahmoudian-Sani MR, Nashibi R et al (2021) Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Immunopharmacol Immunotoxicol 43:247–258. https://doi.org/10.1080/08923973.2021.1925293

doi: 10.1080/08923973.2021.1925293 pubmed: 34015982

Saeedi-Boroujeni A, Nashibi R, Ghadiri AA et al (2022) Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial. Arch Med Res 53:368–377. https://doi.org/10.1016/j.arcmed.2022.03.002

doi: 10.1016/j.arcmed.2022.03.002 pubmed: 35339280 pmcid: 8919799

Sánchez-Fernández A, Skouras DB, Dinarello CA, López-Vales R (2019) OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis. Front Immunol 10:2578. https://doi.org/10.3389/fimmu.2019.02578

doi: 10.3389/fimmu.2019.02578 pubmed: 31736980 pmcid: 6839275

Sandall CF, Ziehr BK, MacDonald JA (2020) ATP-Binding and hydrolysis in inflammasome activation. Molecules 25(19):4572. https://doi.org/10.3390/molecules25194572

doi: 10.3390/molecules25194572 pubmed: 33036374 pmcid: 7583971

Saresella M, La Rosa F, Piancone F et al (2016) The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease. Mol Neurodegener 11:1–14. https://doi.org/10.1186/s13024-016-0088-1

doi: 10.1186/s13024-016-0088-1

Scholz H, Eder C (2017) Lysophosphatidylcholine activates caspase-1 in microglia via a novel pathway involving two inflammasomes. J Neuroimmunol 310:107–110. https://doi.org/10.1016/j.jneuroim.2017.07.004

doi: 10.1016/j.jneuroim.2017.07.004 pubmed: 28778433

Schroder K, Tschopp J (2010) The Inflammasomes. Cell 140:821–832. https://doi.org/10.1016/j.cell.2010.01.040

doi: 10.1016/j.cell.2010.01.040 pubmed: 20303873

Seo BB, Kitajima-Ihara T, Chan EKL et al (1998) Molecular remedy of complex I defects: Rotenone-insensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae mitochondria restores the NADH oxidase activity of complex I-deficient mammalian cells. Proc Natl Acad Sci USA 95:9167–9171. https://doi.org/10.1073/pnas.95.16.9167

doi: 10.1073/pnas.95.16.9167 pubmed: 9689052 pmcid: 21310

Shang S, Wang L, Zhang Y et al (2018) The Beta-Hydroxybutyrate Suppresses the Migration of Glioma Cells by Inhibition of NLRP3 Inflammasome. Cell Mol Neurobiol 38:1479–1489. https://doi.org/10.1007/s10571-018-0617-2

doi: 10.1007/s10571-018-0617-2 pubmed: 30218403

Shen Y, Yang H, Wu D et al (2022) NLRP3 inflammasome inhibitor MCC950 can reduce the damage of pancreatic and intestinal barrier function in mice with acute pancreatitis. Acta Cir Bras 37(7):e370706. https://doi.org/10.1590/acb370706

doi: 10.1590/acb370706 pubmed: 36327405 pmcid: 9633010

Shi J, Zhao Y, Wang K et al (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526:660–665. https://doi.org/10.1038/nature15514

doi: 10.1038/nature15514 pubmed: 26375003

Shi Y, Zhao L, Wang J et al (2022) The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence. Eur J Pharmacol 937:175364. https://doi.org/10.1016/j.ejphar.2022.175364

doi: 10.1016/j.ejphar.2022.175364 pubmed: 36336012

Shim DW, Shin WY, Yu SH et al (2017) BOT-4-one attenuates NLRP3 inflammasome activation: NLRP3 alkylation leading to the regulation of its ATPase activity and ubiquitination. Sci Rep 7:1–12. https://doi.org/10.1038/s41598-017-15314-8

doi: 10.1038/s41598-017-15314-8

Shimada K, Crother TR, Karlin J et al (2012) Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during Apoptosis. Immunity 36:401–414. https://doi.org/10.1016/j.immuni.2012.01.009

doi: 10.1016/j.immuni.2012.01.009 pubmed: 22342844 pmcid: 3312986

Shippy DC, Wilhelm C, Viharkumar PA et al (2020) β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer’s disease pathology. J Neuroinflammation 17:1–12. https://doi.org/10.1186/s12974-020-01948-5

doi: 10.1186/s12974-020-01948-5

Singh S, Jha S (2018) NLRs as helpline in the brain: Mechanisms and therapeutic implications. Mol Neurobiol 55:8154–8178. https://doi.org/10.1007/s12035-018-0957-4

doi: 10.1007/s12035-018-0957-4 pubmed: 29508284

Singh S, Sharma A, Ahmad S et al (2022) Convergence of fructose-induced NLRP3 activation with oxidative stress and ER stress leading to hepatic steatosis. Inflammation 46(1):217–233. https://doi.org/10.1007/s10753-022-01727-9

doi: 10.1007/s10753-022-01727-9 pubmed: 35941320

Singhal G, Jaehne EJ, Corrigan F et al (2014) Inflammasomes in neuroinflammation and changes in brain function: A focused review. Front Neurosci 8:1–22. https://doi.org/10.3389/fnins.2014.00315

doi: 10.3389/fnins.2014.00315

Skokowa J, Cario G, Uenalan M et al (2006) LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 12:1191–1197. https://doi.org/10.1038/nm1484

doi: 10.1038/nm1484 pubmed: 17063141

Söderbom G, Zeng BY (2020) The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases. Int Rev Neurobiol 154:345–391. https://doi.org/10.1016/bs.irn.2020.03.023

doi: 10.1016/bs.irn.2020.03.023 pubmed: 32739011

Sommer N, Alebrahimdehkordi N, Pak O et al (2020) Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. Sci Adv 6(16):eaba0694. https://doi.org/10.1126/sciadv.aba0694

doi: 10.1126/sciadv.aba0694 pubmed: 32426457 pmcid: 7159913

Song L, Pei L, Yao S et al (2017) NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci 11:1–17. https://doi.org/10.3389/fncel.2017.00063

doi: 10.3389/fncel.2017.00063

Starobova H, Nadar EI, Vetter I (2020) The NLRP3 Inflammasome: Role and Therapeutic Potential in Pain Treatment. Front Physiol 11:1–12. https://doi.org/10.3389/fphys.2020.01016

doi: 10.3389/fphys.2020.01016

Stehlik C, Dorfleutner A (2007) COPs and POPs: Modulators of Inflammasome Activity. J Immunol 179:7993–7998. https://doi.org/10.4049/jimmunol.179.12.7993

doi: 10.4049/jimmunol.179.12.7993 pubmed: 18056338

Sternberg EM (2006) Neural regulation of innate immunity: A coordinated nonspecific host response to pathogens. Nat Rev Immunol 6:318–328. https://doi.org/10.1038/nri1810

doi: 10.1038/nri1810 pubmed: 16557263 pmcid: 1783839

Su WJ, Peng W, Gong H et al (2017) Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. J Neuroinflammation 14(1):210. https://doi.org/10.1186/s12974-017-0985-4

doi: 10.1186/s12974-017-0985-4 pubmed: 29084550 pmcid: 5663104

Subba V, Atluri R, Tiwari S et al (2020) Inhibition of amyloid-beta production, associated neuroinflammation, and histone deacetylase 2-mediated epigenetic modifications prevent neuropathology in alzheimer’s disease in vitro model. Front Aging Neurosci 11:342. https://doi.org/10.3389/fnagi.2019.00342

doi: 10.3389/fnagi.2019.00342

Sun Q, Wang S, Chen J et al (2019) MicroRNA-190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP-induced Parkinson’s disease mouse model. J Cell Physiol 234:23379–23387. https://doi.org/10.1002/jcp.28907

doi: 10.1002/jcp.28907 pubmed: 31232472

Sun X, Kang TB, Lee KH (2022) In vitro and in vivo model for sepsis through non-canonical NLRP3 inflammasome activation. Methods Mol Biol 2459:137–147. https://doi.org/10.1007/978-1-0716-2144-8_14

doi: 10.1007/978-1-0716-2144-8_14 pubmed: 35212962

Swanton T, Beswick JA, Hammadi H et al (2020) Selective inhibition of the K+efflux sensitive NLRP3 pathway by Cl-channel modulation. Chem Sci 11:11720–11728. https://doi.org/10.1039/d0sc03828h

doi: 10.1039/d0sc03828h pubmed: 34094411 pmcid: 8162947

Tang T, Lang X, Xu C et al (2017) CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat Commun 8:1–12. https://doi.org/10.1038/s41467-017-00227-x

doi: 10.1038/s41467-017-00227-x

Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H et al (2019) MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol 15:560–564. https://doi.org/10.1038/s41589-019-0278-6

doi: 10.1038/s41589-019-0278-6 pubmed: 31086329 pmcid: 7116292

Teng X, Chen W, Liu Z et al (2018) NLRP3 inflammasome is involved in Q-VD-OPH induced necroptosis following cerebral ischemia-reperfusion injury. Neurochem Res 43:1200–1209. https://doi.org/10.1007/s11064-018-2537-4

doi: 10.1007/s11064-018-2537-4 pubmed: 29802529

Tessarz P, Kouzarides T (2014) Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol 15:703–708. https://doi.org/10.1038/nrm3890

doi: 10.1038/nrm3890 pubmed: 25315270

Tezcan G, Martynova EV, Gilazieva ZE et al (2019) MicroRNA post-transcriptional regulation of the NLRP3 inflammasome in immunopathologies. Front Pharmacol 10:1–22. https://doi.org/10.3389/fphar.2019.00451

doi: 10.3389/fphar.2019.00451

Theodoropoulou K, Wittkowski H, Busso N et al (2020) Increased prevalence of NLRP3 Q703K variant among patients with autoinflammatory diseases: an international multicentric study. Front Immunol 11:877. https://doi.org/10.3389/fimmu.2020.00877

doi: 10.3389/fimmu.2020.00877 pubmed: 32477355 pmcid: 7241420

Tohidpour A, Morgun AV, Boitsova EB et al (2017) Neuroinflammation and infection: Molecular mechanisms associated with dysfunction of neurovascular unit. Front Cell Infect Microbiol 7:276. https://doi.org/10.3389/fcimb.2017.00276

doi: 10.3389/fcimb.2017.00276 pubmed: 28676848 pmcid: 5476750

Toldo S, Abbate A (2018) The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol 15:203–214. https://doi.org/10.1038/nrcardio.2017.161

doi: 10.1038/nrcardio.2017.161 pubmed: 29143812

Touitou I, Lesage S, McDermott M et al (2004) Infevers: An evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24:194–198. https://doi.org/10.1002/humu.20080

doi: 10.1002/humu.20080 pubmed: 15300846

Voet S, Srinivasan S, Lamkanfi M, Loo G (2019) Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med 11:1–16. https://doi.org/10.15252/emmm.201810248

doi: 10.15252/emmm.201810248

Vogel S, Kamimura S, Arora T et al (2021) NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice. Biochem Biophys Res Commun 555:196–201. https://doi.org/10.1016/j.bbrc.2021.03.115

doi: 10.1016/j.bbrc.2021.03.115 pubmed: 33831782 pmcid: 8085042

Walsh JG, Muruve DA, Power C (2014) Inflammasomes in the CNS. Nat Rev Neurosci 15:84–97. https://doi.org/10.1038/nrn3638

doi: 10.1038/nrn3638 pubmed: 24399084

Wang D, Wang H, Fu S et al (2016) Parthenolide ameliorates Concanavalin A-induced acute hepatitis in mice and modulates the macrophages to an anti-inflammatory state. Int Immunopharmacol 38:132–138. https://doi.org/10.1016/j.intimp.2016.05.024

doi: 10.1016/j.intimp.2016.05.024 pubmed: 27270078

Wang J, Liao AM, Thakur K et al (2019a) Licochalcone B Extracted from Glycyrrhiza uralensis Fisch Induces Apoptotic Effects in Human Hepatoma Cell HepG2. J Agric Food Chem 67:3341–3353. https://doi.org/10.1021/acs.jafc.9b00324

doi: 10.1021/acs.jafc.9b00324 pubmed: 30835110

Wang L, Hauenstein AV (2020) The NLRP3 inflammasome: mechanism of action, role in disease and therapies. Mol Aspects Med 76:100889. https://doi.org/10.1016/j.mam.2020.100889

doi: 10.1016/j.mam.2020.100889 pubmed: 32859386

Wang M, Zhao M, Yu J et al (2022a) MCC950, a selective NLRP3 inhibitor, attenuates adverse cardiac remodeling following heart failure through improving the cardiometabolic dysfunction in obese mice. Front Cardiovasc Med 9:727474. https://doi.org/10.3389/fcvm.2022.727474

doi: 10.3389/fcvm.2022.727474 pubmed: 35647084 pmcid: 9133382

Wang S, Yang H, Yu L et al (2014) Oridonin attenuates Aβ1-42-induced neuroinflammation and inhibits NF-κB pathway. PLoS One 9:1–7. https://doi.org/10.1371/journal.pone.0104745

doi: 10.1371/journal.pone.0104745

Wang S, Yuan YH, Chen NH, Wang HB (2019b) The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. Int Immunopharmacol 67:458–464. https://doi.org/10.1016/j.intimp.2018.12.019

doi: 10.1016/j.intimp.2018.12.019 pubmed: 30594776

Wang S, Zhang Y, Saas P et al (2015) Oridonin’s therapeutic effect: Suppressing Th1/Th17 simultaneously in a mouse model of Crohn’s disease. J Gastroenterol Hepatol 30:504–512. https://doi.org/10.1111/jgh.12710

doi: 10.1111/jgh.12710 pubmed: 25211373

Wang W, Kwon EJ, Tsai LH (2012) MicroRNAs in learning, memory, and neurological diseases. Learn Mem 19:359–368. https://doi.org/10.1101/lm.026492.112

doi: 10.1101/lm.026492.112 pubmed: 22904366

Wang X, Sun K, Zhou Y et al (2021) NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. Biochem Biophys Res Commun 534:734–739. https://doi.org/10.1016/j.bbrc.2020.11.009

doi: 10.1016/j.bbrc.2020.11.009 pubmed: 33213837

Wang X, Wang Q, Li W et al (2020a) TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone i in doxorubicin-induced cardiotoxicity. J Exp Clin Cancer Res 39(1):93. https://doi.org/10.1186/s13046-020-01595-x

doi: 10.1186/s13046-020-01595-x pubmed: 32448281 pmcid: 7245789

Wang Y, Liu YJ, Zhang MM et al (2022b) CY-09 alleviates the depression-like behaviors via inhibiting NLRP3 inflammasome-mediated neuroinflammation in lipopolysaccharide-induced mice. ACS Chem Neurosci 13(23):3291–3302. https://doi.org/10.1021/acschemneuro.2c00348

doi: 10.1021/acschemneuro.2c00348 pubmed: 36399525

Wang Y, Zeng Z, Ran J et al (2022c) The critical role of potassium efflux and nek7 in pasteurella multocida-induced NLRP3 inflammasome activation. Front Microbiol 13:849482. https://doi.org/10.3389/fmicb.2022.849482

doi: 10.3389/fmicb.2022.849482 pubmed: 35350616 pmcid: 8957907

Wang Z, Zhang S, Xiao Y et al (2020b) NLRP3 Inflammasome and inflammatory diseases. Oxid Med Cell Longev 2020:4063562. https://doi.org/10.1155/2020/4063562

doi: 10.1155/2020/4063562 pubmed: 32148650 pmcid: 7049400

Wang ZY, Lian Y, Wang LJ et al (2022d) Protective effect of MCC950 on Acute Pancreatitis in Rats and its Molecular Mechanism. Chinese J Pharm Biotechnol 29. https://doi.org/10.19526/j.cnki.1005-8915.20220208

Welcome MO (2020) Neuroinflammation in CNS diseases: Molecular mechanisms and the therapeutic potential of plant derived bioactive molecules. PharmaNutrition 11:100176. https://doi.org/10.1016/j.phanu.2020.100176

doi: 10.1016/j.phanu.2020.100176

Wu X, Wang B, Zhou Y et al (2023) NLRP3 inflammasome inhibitor MCC950 reduces cerebral ischemia/reperfusion induced neuronal ferroptosis. Neurosci Lett 795:137032. https://doi.org/10.1016/j.neulet.2022.137032

doi: 10.1016/j.neulet.2022.137032 pubmed: 36581063

Wu Y, Teng Y, Zhang C et al (2022) The ketone body β-hydroxybutyrate alleviates CoCrMo alloy particles induced osteolysis by regulating NLRP3 inflammasome and osteoclast differentiation. J Nanobiotechnology 20(1):120. https://doi.org/10.1186/s12951-022-01320-0

doi: 10.1186/s12951-022-01320-0 pubmed: 35264201 pmcid: 8905851

Xagorari A, Papapetropoulos A, Mauromatis A et al (2001) Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 296:181–187

pubmed: 11123379

Xiao L, Zheng H, Li J et al (2020) Neuroinflammation mediated by NLRP3 inflammasome after intracerebral hemorrhage and potential therapeutic targets. Mol Neurobiol 57:5130–5149. https://doi.org/10.1007/s12035-020-02082-2

doi: 10.1007/s12035-020-02082-2 pubmed: 32856203

Xie XJ, Ma LG, Xi K et al (2017) Effects of microRNA-223 on morphine analgesic tolerance by targeting NLRP3 in a rat model of neuropathic pain. Mol Pain 13:1744806917706582. https://doi.org/10.1177/1744806917706582

doi: 10.1177/1744806917706582 pubmed: 28580822 pmcid: 5464520

Xu C, Zhou Z, Zhao H et al (2023) Zinc promotes spinal cord injury recovery by blocking the activation of NLRP3 inflammasome through SIRT3-mediated autophagy. Neurochem Res 48:435–446. https://doi.org/10.1007/s11064-022-03762-2

doi: 10.1007/s11064-022-03762-2 pubmed: 36152137

Xu X, Yin D, Ren H et al (2018) Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury. Neurobiol Dis 117:15–27. https://doi.org/10.1016/j.nbd.2018.05.016

doi: 10.1016/j.nbd.2018.05.016 pubmed: 29859317

Xu Y, Xue Y, Wang Y et al (2009) Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol 9:360–365. https://doi.org/10.1016/j.intimp.2009.01.002

doi: 10.1016/j.intimp.2009.01.002 pubmed: 19185062

Yamamoto S, Yamashina K, Ishikawa M et al (2017) Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease. J Neuroinflammation 14(1):142. https://doi.org/10.1186/s12974-017-0923-5

doi: 10.1186/s12974-017-0923-5 pubmed: 28732510 pmcid: 5521126

Yamanashi T, Iwata M, Kamiya N et al (2017) Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. Sci Rep 7(1):7677. https://doi.org/10.1038/s41598-017-08055-1

doi: 10.1038/s41598-017-08055-1 pubmed: 28794421 pmcid: 5550422

Yamanashi T, Iwata M, Shibushita M, et al (2020) Beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, attenuates anxiety-related behavior in a rodent post-traumatic stress disorder model. Sci Rep 10:. https://doi.org/10.1038/s41598-020-78410-2

Yan C, Yan H, Mao J et al (2020) Neuroprotective effect of oridonin on traumatic brain injury via inhibiting NLRP3 inflammasome in experimental mice. Front Neurosci 14:557170. https://doi.org/10.3389/fnins.2020.557170

doi: 10.3389/fnins.2020.557170 pubmed: 33281541 pmcid: 7691250

Yan W, Shen Y, Huang J et al (2021) MCC950 Ameliorates acute liver injury through modulating macrophage polarization and myeloid-derived suppressor cells function. Front Med 8:752223. https://doi.org/10.3389/fmed.2021.752223

doi: 10.3389/fmed.2021.752223

Yang H, Lv H, Li H et al (2019a) Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways. Cell Commun Signal 17(1):62. https://doi.org/10.1186/s12964-019-0366-y

doi: 10.1186/s12964-019-0366-y pubmed: 31186013 pmcid: 6558832

Yang R, Yang B, Liu W et al (2023) Emerging role of non-coding RNAs in neuroinflammation mediated by microglia and astrocytes. J Neuroinflammation 20(1):173. https://doi.org/10.1186/s12974-023-02856-0

doi: 10.1186/s12974-023-02856-0 pubmed: 37481642 pmcid: 10363317

Yang S, Xie C, Guo T et al (2022) Simvastatin inhibits tumor growth and migration by mediating caspase-1–dependent pyroptosis in glioblastoma multiforme. World Neurosurg 165:e12–e21. https://doi.org/10.1016/j.wneu.2022.03.089

doi: 10.1016/j.wneu.2022.03.089 pubmed: 35342027

Yang X, Lin G, Han Z, Chai J (2019b) Structural biology of NOD-like receptors. Adv Exp Med Biol 1172:119–141. https://doi.org/10.1007/978-981-13-9367-9_6

doi: 10.1007/978-981-13-9367-9_6 pubmed: 31628654

Yang X, Qu C, Jia J, Zhan Y (2019c) NLRP3 inflammasome inhibitor glyburide expedites diabetic-induced impaired fracture healing. Immunobiology 224:786–791. https://doi.org/10.1016/j.imbio.2019.08.008

doi: 10.1016/j.imbio.2019.08.008 pubmed: 31477246

Yang X, Wang R, Zhou H et al (2021) β-hydroxybutyrate alleviates learning and memory impairment through the SIRT1 pathway in D-galactose-injured mice. Front Pharmacol 12:751028. https://doi.org/10.3389/fphar.2021.751028

doi: 10.3389/fphar.2021.751028 pubmed: 34880753 pmcid: 8645592

Yang Y, Wang H, Kouadir M et al (2019d) Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 10(2):128. https://doi.org/10.1038/s41419-019-1413-8

doi: 10.1038/s41419-019-1413-8 pubmed: 30755589 pmcid: 6372664

Yang Z, Zhong L, Xian R, Yuan B (2015) MicroRNA-223 regulates inflammation and brain injury via feedback to NLRP3 inflammasome after intracerebral hemorrhage. Mol Immunol 65:267–276. https://doi.org/10.1016/j.molimm.2014.12.018

doi: 10.1016/j.molimm.2014.12.018 pubmed: 25710917

Ye X, Zuo D, Yu L et al (2017) ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia. Biochem Biophys Res Commun 485:499–505. https://doi.org/10.1016/j.bbrc.2017.02.019

doi: 10.1016/j.bbrc.2017.02.019 pubmed: 28202418

Youm YH, Nguyen KY, Grant RW et al (2015) The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21:263–269. https://doi.org/10.1038/nm.3804

doi: 10.1038/nm.3804 pubmed: 25686106 pmcid: 4352123

Yu Q, Zhao T, Liu M et al (2021) Targeting NLRP3 inflammasome in translational treatment of nervous system diseases: an update. Front Pharmacol 12:707696. https://doi.org/10.3389/fphar.2021.707696

doi: 10.3389/fphar.2021.707696 pubmed: 34526897 pmcid: 8435574

Zeng R, Luo DX, Li HP et al (2019) MicroRNA-135b alleviates MPP+-mediated Parkinson’s disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. J Clin Neurosci 65:125–133. https://doi.org/10.1016/j.jocn.2019.04.004

doi: 10.1016/j.jocn.2019.04.004 pubmed: 31036506

Zeng W, Wu D, Sun Y et al (2021) The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci Rep 11(1):19305. https://doi.org/10.1038/s41598-021-98437-3

doi: 10.1038/s41598-021-98437-3 pubmed: 34588488 pmcid: 8481539

Zewinger S, Reiser J, Jankowski V et al (2020) Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol 21:30–41. https://doi.org/10.1038/s41590-019-0548-1

doi: 10.1038/s41590-019-0548-1 pubmed: 31819254

Zhang A, Lu Y, Yuan L et al (2021a) MiR-29a-5p Alleviates traumatic brain injury-(TBI-) induced permeability disruption via regulating NLRP3 pathway. Dis Markers 2021:9556513. https://doi.org/10.1155/2021/9556513

doi: 10.1155/2021/9556513 pubmed: 34876932 pmcid: 8645411

Zhang A, Wang K, Ding L et al (2017) Bay11-7082 attenuates neuropathic pain via inhibition of nuclear factor-kappa B and nucleotide-binding domain-like receptor protein 3 inflammasome activation in dorsal root ganglions in a rat model of lumbar disc herniation. J Pain Res 10:375–382. https://doi.org/10.2147/JPR.S119820

doi: 10.2147/JPR.S119820 pubmed: 28243141 pmcid: 5315342

Zhang L, Jiang YH, Fan C et al (2021b) MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed Pharmacother 143:112133. https://doi.org/10.1016/j.biopha.2021.112133

doi: 10.1016/j.biopha.2021.112133 pubmed: 34474337

Zhang P, Cao L, Zhou R et al (2019) The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun 10(1):1495. https://doi.org/10.1038/s41467-019-09482-6

doi: 10.1038/s41467-019-09482-6 pubmed: 30940803 pmcid: 6445148

Zhang X, Wang R, Hu D et al (2020a) Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer’s disease. Sci Adv 6(49):eabb8680. https://doi.org/10.1126/sciadv.abb8680

doi: 10.1126/sciadv.abb8680 pubmed: 33277246 pmcid: 7717916

Zhang Y, Dong Z, Song W (2020b) NLRP3 Inflammasome as a novel therapeutic target for Alzheimer’s disease. Signal Transduct Target Ther 5(1):37. https://doi.org/10.1038/s41392-020-0145-7

doi: 10.1038/s41392-020-0145-7 pubmed: 32296063 pmcid: 7109024

Zhang Y, Lin Z, Chen D, He Y (2021c) CY-09 attenuates the progression of osteoarthritis via inhibiting NLRP3 inflammasome-mediated pyroptosis. Biochem Biophys Res Commun 553:119–125. https://doi.org/10.1016/j.bbrc.2021.03.055

doi: 10.1016/j.bbrc.2021.03.055 pubmed: 33765556

Zhang Y, Zhao Y, Zhang J, Yang G (2020c) Mechanisms of NLRP3 inflammasome activation: Its role in the treatment of alzheimer’s disease. Neurochem Res 45:2560–2572. https://doi.org/10.1007/s11064-020-03121-z

doi: 10.1007/s11064-020-03121-z pubmed: 32929691

Zhang ZY, Daniels R, Schluesener HJ (2013) Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J Cell Mol Med 17:1566–1576. https://doi.org/10.1111/jcmm.12124

doi: 10.1111/jcmm.12124 pubmed: 24034629 pmcid: 3914648

Zhao G, Zhang T, Ma X et al (2017) Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury. Oncotarget 8:68153–68164. https://doi.org/10.18632/oncotarget.19249

doi: 10.18632/oncotarget.19249 pubmed: 28978105 pmcid: 5620245

Zhao J, Liu H, Hong Z et al (2022) Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC. SSRN Electron J 29(1):84. https://doi.org/10.2139/ssrn.4220591

doi: 10.2139/ssrn.4220591

Zhao J, Wang H, Dong L et al (2019) MiRNA-20b Inhibits cerebral ischemia-induced inflammation through targeting NLRP3. Int J Mol Med 43:1167–1178. https://doi.org/10.3892/ijmm.2018.4043

doi: 10.3892/ijmm.2018.4043 pubmed: 30628668

Zheng J, Jiang Z, Song Y et al (2022) 3,4-Methylenedioxy-β-Nitrostyrene alleviates dextran sulfate sodium–induced mouse colitis by inhibiting the NLRP3 inflammasome. Front Pharmacol 13:866228. https://doi.org/10.3389/fphar.2022.866228

doi: 10.3389/fphar.2022.866228 pubmed: 35784693 pmcid: 9240698

Zheng X, Wan J, Tan G (2023) The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy. Front Immunol 14:1151185. https://doi.org/10.3389/fimmu.2023.1151185

doi: 10.3389/fimmu.2023.1151185 pubmed: 37180116 pmcid: 10167027

Zhong Z, Liang S, Sanchez-Lopez E et al (2018) New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560:198–203. https://doi.org/10.1038/s41586-018-0372-z

doi: 10.1038/s41586-018-0372-z pubmed: 30046112 pmcid: 6329306

Zhou K, Shi L, Wang Y et al (2016a) Recent advances of the NLRP3 inflammasome in central nervous system disorders. J Immunol Res 2016:9238290. https://doi.org/10.1155/2016/9238290

doi: 10.1155/2016/9238290 pubmed: 27652274 pmcid: 5019917

Zhou R, Tardivel A, Thorens B et al (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11:136–140. https://doi.org/10.1038/ni.1831

doi: 10.1038/ni.1831 pubmed: 20023662

Zhou R, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221–226. https://doi.org/10.1038/nature09663

doi: 10.1038/nature09663 pubmed: 21124315

Zhou Y, Lu M, Du RH et al (2016b) MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener 11:1–15. https://doi.org/10.1186/s13024-016-0094-3

doi: 10.1186/s13024-016-0094-3

Zhu H, Jian Z, Zhong Y et al (2021) Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition. Front Immunol 12:714943. https://doi.org/10.3389/fimmu.2021.714943

doi: 10.3389/fimmu.2021.714943 pubmed: 34367186 pmcid: 8339584

New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Informations de copyright

Références

Auteurs

Triveni Kodi (T)

Runali Sankhe (R)

Adarsh Gopinathan (A)

Krishnadas Nandakumar (K)

Anoop Kishore (A)

Classifications MeSH